Synthomer Sells William Blythe Unit to Refocus on Core Specialty Chemicals Business

 

Synthomer plc (LSE:SYNT) has announced the sale of its inorganic chemicals subsidiary, William Blythe Limited, to a combination of its current management and H2 Equity Partners for a total consideration of £30 million. The transaction, expected to close by the end of May 2025, is part of Synthomer’s broader strategy to streamline operations and sharpen its focus on high-growth specialty chemicals. Proceeds from the deal will be used to reduce net debt, supporting the company’s ongoing financial restructuring.

This divestment represents a key milestone in Synthomer’s strategic transformation, aimed at simplifying its portfolio and reinforcing its position in performance polymer markets. Despite the operational shift, the company continues to face financial headwinds, including pressure on profitability and cash flow. While recent management actions suggest confidence in long-term recovery, negative market momentum and valuation challenges have dampened investor sentiment.

About Synthomer plc

Synthomer is a global producer of high-performance polymers and ingredients, supplying industries such as coatings, adhesives, construction, and healthcare. Headquartered in London, the company has been listed on the London Stock Exchange since 1971 and employs around 4,000 people across 31 production sites and five innovation centers. Synthomer focuses on sustainable innovation, with a growing share of revenue coming from patented and environmentally aligned products.

• Year-to-Date Performance: -42.24%

• Average Daily Trading Volume: 797,904 shares

• Technical Rating: Buy

• Market Capitalization: £152.1 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  ForexSQ

• 

  Mark Austin

• 

  Sunil Mangwani

• 

  ADVFN Tech News